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New vaccines against tuberculosis are urgently required because of the impressive incidence of this disease
worldwide and the highly variable protective efficacy of the current vaccine. The possibility of creating new live
vaccines by the rational attenuation of strains from the Mycobacterium tuberculosis complex was investigated.
Two auxotrophic mutants of M. tuberculosis and M. bovis BCG were constructed by disruption of one of their
purine biosynthetic genes. These mutants appeared unable to multiply in vitro within mouse bone-marrow
derived macrophages. They were also attenuated in vivo in the mouse and guinea pig animal models. In guinea
pigs, the two mutants induced strong delayed-type hypersensitivity response to purified protein derivative. In
a preliminary experiment, the two mutants were compared to the BCG vaccine for their protective efficacy in
a challenge against aerosolized virulent M. tuberculosis in the guinea pig model. Both mutants conferred some
level of protection. These experiments demonstrate that the rational attenuation of M. tuberculosis could lead
to the design of new candidate live vaccines against tuberculosis.
Mycobacterium tuberculosis, the etiological agent of tubercu-
losis (TB), remains an important cause of human mortality and
morbidity. Worldwide, 60 million people suffer from active TB
and annually 7 million new cases arise (10). The World Health
Organization estimate is about 3 million deaths per year due to
TB, of which more than 95% occur in developing countries. In
industrialized countries, the declining incidence which had
been observed since the beginning of the century was reversed
in the mid-1980s due in part to impaired social conditions and
the increasing frequency of AIDS (15).
Efficient chemotherapy exists but requires lengthy and ex-
pensive treatments, making its widespread use and control
difficult to achieve in developing countries. Prophylactic vacci-
nation against TB with the attenuated strain of bovine myco-
bacteria, BCG (Mycobacterium bovis Bacillus Calmette-
Gue´rin), is more cost-effective and has indeed been used
worldwide. Although BCG vaccination has provided protec-
tion against TB in certain populations, the variation in efficacy
of this vaccine in different field trials and its modest protective
effect against the adult form of the disease (estimated by meta-
analysis to be about 50%) (8) are points of major concern.
These considerations have led the World Health Organization
to place TB control efforts, notably through the development
of new vaccines, among its top priorities.
In the recent years, considerable efforts have been made
toward the identification of individual mycobacterial antigens
involved in the immune response to TB (25) with the aim of
developing subunit vaccines. An alternative strategy to develop
novel vaccines consists of constructing mutant strains of my-
cobacteria that are rationally attenuated. The recent develop-
ment of genetic tools for performing site-specific and random-
site mutagenesis (4, 22) in organisms from the M. tuberculosis
complex now renders feasible the accomplishment of such a
goal. Live vaccines should have advantages over subunit vac-
cines in that (i) they represent a greater pool of antigens which
presumably should cover a wider range of T-cell repertoires
and (ii) they are generally more cost-effective to produce.
Moreover, attenuated mutants of M. tuberculosis should ex-
press homologous protective antigens which other mycobacte-
rial strains lack and thus elicit a more specific and perhaps
stronger protective immune response against virulence chal-
lenge. In support of this hypothesis, the molecular analysis by
Mahairas and collaborators (16) of genetic differences between
M. bovis BCG and its virulent counterparts M. bovis and M.
tuberculosis clearly established the existence of regions of de-
letion in the genome of BCG (representing about 30 kb in all),
some of which contain the open reading frames encoding the
highly immunogenic ESAT 6 and mpt64 antigens (the latter
being absent from certain BCG strains only [21]).
Among attenuated strains of intracellular bacterial patho-
gens, such as salmonellae, yersiniae, brucellae, and corynebac-
teria (6, 9, 12, 18, 20, 23), auxotrophic mutants carrying defects
in the shikimate or the purine biosynthetic pathways were
shown to be of particular interest as potential live vaccines
candidates because they are attenuated in vivo and have the
ability to retain their immunogenicity.
In mycobacteria, the only available attenuated auxotrophs
are M. bovis BCG derivatives (11, 17). A BCG auxotroph
carrying a defect in the leucine biosynthetic pathway was un-
able to grow in C57BL/6 mice (17) and to replicate inside
human THP1 macrophages (2). This mutant, as well as other
leucine, methionine, and isoleucine-leucine-valine auxotrophs
of BCG, were also shown to be cleared from the organs of mice
with severe combined immunodeficiency disease (SCID mice);
in contrast, the mice succumbed to the wild-type BCG within 8
weeks. In addition, immunization with these mutants provided
BALB/c mice protection against a challenge with M. tubercu-
losis (11). These results led the authors to propose that the
attenuated BCG strains could represent potentially safe and
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useful vaccines against TB for populations at risk for infection
with human immunodeficiency virus. In M. tuberculosis, a
leucine auxotroph was obtained by allelic exchange (1), but
unlike its BCG counterpart, it showed no significant difference
from the parental wild-type strain with respect to growth in
SCID mice, producing a fatal infection (3).
In a previous report, we described the isolation and charac-
terization of two genes from the M. tuberculosis purine biosyn-
thetic pathway, purC and purL (13). We also reported the
construction by allelic exchange of a purC mutant of M. tuber-
culosis (22). In this paper, we describe the construction of a
purC mutant of M. bovis BCG and provide evidence that both
the M. tuberculosis and M. bovis purine auxotrophs are affected
in their survival inside mouse bone marrow macrophages and
in vivo in mice and guinea pigs. The delayed-type hypersensi-
tivity (DTH) responses to purified protein derivative (PPD)
induced by both mutants in a guinea pig model was investi-
gated at 9 weeks postvaccination. Finally, the level of protec-
tive immunity elicited by the two auxotrophs against low-dose
pulmonary challenge with virulent M. tuberculosis was evalu-
ated in a guinea pig model of TB.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Escherichia coli XL1-Blue and the
mycobacterial strains M. bovis BCG strain Pasteur 1173P2, M. tuberculosis
MT103 (isolated from a TB patient), and H37Rv (ATCC 27294) were cultured
as previously described (22). When required, kanamycin (20 mg/ml), gentamicin
(10 mg/ml), or hypoxanthine (20 mg/ml), a purine precursor, was added to the
growth medium.
Plasmid construction. Plasmid pMJ110 was constructed by inserting the 3.7-kb
BamHI fragment containing purC::Km from pMJ101 into the BamHI site of
pJQ200 (22). This plasmid is unable to replicate in mycobacteria. Plasmid
pMJ111 was created by excising the 1,090-bp EcoRV-HincII fragment from
plasmid pMJ1, harboring the purC gene flanked by 120 bp upstream and 80 bp
downstream, and cloning it into plasmid pOMK (13). pMJ111 is able to replicate
in mycobacteria.
Preparation and infection of mouse bone marrow macrophages. Bone marrow
cells were flushed from the femurs of 7- to 8-week-old BALB/c mice (purchased
from Iffa Credo, l’Arbresle, France) and suspended in Dulbecco medium with
low glucose (1 g/liter) and high carbonate (3.7 g/liter) concentrations (Gibco
BRL) and enriched with 10% heat-inactivated fetal calf serum (Dominique
Dutscher), 10% L-cell conditioned medium, and 2 mM glutamine. For the
infection assays, mouse bone marrow macrophages were seeded in eight-well
Lab-Tek chamber slides (Nalgene Nunc International) (5 3 104 cells/well) and
infected with bacterial suspensions of either MT103, BCG 1173P2, MYC1551, or
MYC1552 at a multiplicity of infection of 1:1. Cultures were incubated at 37°C
in a 5% CO2 atmosphere. After 18 h, infection was terminated by removing the
overlaying medium and washing each well three times with 500 ml of Hanks’
buffered salt solution (Gibco BRL) before adding 400 ml of fresh culture medium
per well. At days 1 (18 h), 4, 7, and 11, the number of intracellular CFU was
evaluated by plating appropriate dilutions of lysed macrophages (in cell culture
lysis reagent [Promega]) onto 7H10 or 7H10 supplemented with hypoxanthine.
At each time point, a Lab-Tek chamber slide containing infected macrophages
and cultivated in the same conditions was subjected to staining for acid-fast
bacilli in order to check macrophage viability. This infection experiment was
carried out in duplicate.
Mycobacterial multiplication in mice. C57BL/6j or BALB/c female mice (6 to
8 weeks old; purchased from CERJ, Le Genest St Isle, France, or Iffa Credo)
were infected intravenously either with 105 CFU of MYC1551 and MT103 or
with 107 CFU of MYC1552 and BCG in 0.5 ml of phosphate saline buffer. At
every time point, mice were euthanized with CO2, and the spleen, lung, and liver
were removed aseptically and homogenized either manually, using two glass
slides (for the spleen and lung), or in a Stomacher 80 (Seward) homogenizer (for
the liver). Bacteria in the organs of infected animals were enumerated by plating
10-fold serial dilutions of organ homogenates onto 7H11 medium (supplemented
with hypoxanthine for the auxotroph mutants). The data were expressed as the
geometric means 6 standard errors of the means (SEM) of counts obtained with
five to six mice.
Vaccination, challenge, and necropsy of guinea pigs. Male and female outbred
Hartley strain guinea pigs (Charles River Laboratories, Inc., Wilmington, Mass.)
were used. Guinea pigs were injected subcutaneously into the inguinal region
with approximately 107 CFU of either wild-type BCG, the corresponding BCG
auxotrophic strain MYC1552, or the M. tuberculosis auxotrophic mutant
MYC1551 in a volume of 0.2 ml. Three, six, and nine weeks postvaccination,
three animals from each of the three vaccine groups were euthanized. The
number of viable mycobacteria carried by one-half of the spleen and the right
lower lobe of the lung was determined by inoculating appropriate dilutions of
organ homogenates onto duplicate 7H10 plates supplemented with hypoxan-
thine. Nine weeks postvaccination, all animals were infected via the respiratory
route with an infecting inoculum of viable H37Rv (empirically adjusted to result
in the inhalation of 5 to 10 viable organisms per animal) by use of an aerosol
chamber as previously described (24). Five weeks after respiratory challenge,
animals were euthanized, and the spleen and right lower lobe of the lung were
removed for bacterial culture.
Tuberculin skin test. The DTH reaction was evaluated by the intradermal
injection of 0.1 ml of PPD containing 100 tuberculin units (RT-23; Statens
Seruminstitut) on a shaved area of the abdomen. The mean diameter of indu-
ration was measured in millimeters and recorded 24 h later.
Statistical methods. Analysis of variance was used to test the effects of vacci-
nation on tissue bacterial load. When significant treatment effects were indicated,
differences between means were assessed by Duncan’s multiple-range test. A
95% confidence level was set for all tests. All analyses were performed with PC
SAS 6.12 (SAS Institute, Cary, N.C.).
RESULTS
Construction of purC mutants of M. bovis BCG and M.
tuberculosis. An M. bovis BCG purC mutant was obtained by
using a classical allelic exchange procedure consisting in the
transformation of the wild-type strain M. bovis BCG 1173P2
with a suicide vector carrying a disrupted copy of the purC gene
(purC::Km) and selecting for kanamycin-resistant (Kmr) trans-
formants on 7H10 plates containing kanamycin and hypoxan-
thine. M. bovis BCG 1173P2 was electroporated by using 2 mg
of plasmid pMJ110. Two Kmr transformants were obtained.
Their genomic DNAs were extracted and analyzed by Southern
blotting using the purC gene as a probe (Fig. 1). One of the two
FIG. 1. Southern blot analysis and hybridization profile of the M. bovis BCG
purC mutant. The hybridization profiles of the DNA of Kmr transformants
obtained in two independent experiments are shown. Lane 1 corresponds to the
M. bovis BCG purC mutant MYC1552; lanes 2 to 4 correspond to transformants
which have undergone a single crossover event at the purC locus in another
experiment; lane 5 is the wild-type (WT) strain M. bovis BCG 1173P2. Chromo-
somal DNA were digested with BamHI and probed for hybridization with the
purC gene (1,090-bp EcoRV-HincII fragment from pMJ1).
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clones exhibited the correct hybridization pattern for an allelic
exchange mutant. The other one corresponded to the wild type
and was probably a Kmr mutant of M. bovis BCG. The candi-
date clone was phenotypically tested. As expected, it required
purines or hypoxanthine (a precursor of purine bases) to grow
on 7H9 or 7H10 (Fig. 2). This mutant was renamed MYC1552.
The purC mutant of M. tuberculosis MT103, named
MYC1551, was obtained as described by Pelicic et al. (22).
Like MYC1552, MYC1551 is dependent on the presence of
purines or hypoxanthine in the medium to multiply (Fig. 2).
Evaluation of the reversion frequency of MYC1551 and
MYC1552. To estimate the stability of the mutation introduced
by allelic exchange in M. bovis BCG and M. tuberculosis, cul-
tures of MYC1551 and MYC1552 grown in 7H9 containing
kanamycin were plated on 7H10 with kanamycin and hypoxan-
thine or 7H10 alone. In all the experiments (repeated inde-
pendently four and two times for MYC1552 and MYC1551,
respectively), no CFU was detected on 7H10 whereas 2 3 108
and 4 3 108 CFU in all were obtained for MYC1551 and
MYC1552, respectively, on 7H10 supplemented with hypoxan-
thine and kanamycin. Therefore, the reversion frequency was
estimated to be lower than 1028 events per cell and per gen-
eration. The same experiment was repeated with cultures
grown in 7H9 liquid medium without kanamycin, and the same
results were obtained.
Growth characteristics of the purine auxotrophs in macro-
phages. The ability of the purine auxotrophs to persist and
multiply within bone marrow macrophages from C57BL/6j
mice was evaluated. Macrophages (5 3 104) were infected at a
multiplicity of infection, of close to 1 with the parental and the
mutant strains. Over a period of 15 days, the infection was
followed by counting the viable bacteria (Fig. 3).
M. tuberculosis MT103 and M. bovis BCG 1137P2 multiplied
within the macrophage with apparent doubling times of 36 and
59 h, respectively. At 8 days postinfection, macrophages were
packed with M. tuberculosis, and most of them lysed. With M.
bovis BCG, the infection was followed for 15 days without
apparent lysis of the macrophages. The purine auxotrophs
exhibited growth characteristics totally different from those of
their parental strains. In both cases, infections were contained.
The M. tuberculosis purC mutant MYC1551 persisted, but the
number of viable bacteria did not increase. The M. bovis BCG
purC mutant MYC1552 was gradually eliminated, and after 15
days less than 3% of the inoculum was still viable. These results
demonstrate that disruption of the purC gene alters the ability
of M. tuberculosis and M. bovis BCG to multiply within mouse
bone marrow macrophages.
To confirm that this phenotype was due to the mutation of
the purC gene and not to a polar effect of the kan gene inser-
tion, a complementation experiment was performed. Plasmid
pMJ111 containing purC was electrotransferred into MYC1551.
Transformants no longer required purines to grow in 7H9 or
7H10 (Fig. 2). MYC1551 (pMJ111) was used to infect macro-
phages (Fig. 3B). As expected, the presence of purC on the
plasmid fully restored the ability of MYC1551 to multiply
within macrophages.
Persistence of the auxotroph mutants and their parental
counterparts in mice. M. tuberculosis (105 CFU) and M. bovis
BCG (107 CFU) were used to infect BALB/c mice intrave-
nously. The mice were killed at different time points, and
viable bacteria in the liver, spleen, and lung were counted (Fig.
4 and 5).
For wild-type M. tuberculosis (Fig. 4), there was a large
increase in the number of CFU in the three organs during the
first 2 or 3 weeks: 2.5 logs in the spleen (day 14), 1 log in the
liver (day 14), and 3 logs in the lung (day 21). At this time, the
infection was controlled; the bacillary load was stabilized in
both the lung and the spleen at 106 and 105 CFU per organ,
respectively. In the liver, the bacterial burden decreased to
reach a plateau at 104 CFU. For the M. tuberculosis purine
auxotroph MYC1551, the situation was quite different. The
initial multiplication was dramatically reduced, with less than
0.5-log increase in every organ at the peak occurring at day 7.
The bacilli were then gradually eliminated from the three or-
gans, becoming undetectable at day 63.
For BCG (Fig. 5), the initial multiplication was slower than
for M. tuberculosis: only 0.5-log increase in the spleen at day 14
and almost no multiplication in the lung and the liver. From
day 14 in both the liver and the spleen and from day 28 in the
lung, the number of viable bacilli decreased gradually, reaching
5 3 103, 104, and 5 3 104 in the lung, liver, and spleen,
FIG. 2. Growth kinetics of MYC1552, MYC1551, MYC1551(pMJ111), and
their wild-type counterparts grown in 7H9 medium in the absence or presence of
the purine precursor hypoxanthine. The different strains were grown in 7H9
medium (supplemented with hypoxanthine for MYC1551 and MYC1552) to an
optical density at 600 nm (OD600) of close to 1. These cultures were diluted in
fresh medium in the absence or presence of hypoxanthine (Hx) to reach an
OD600 of 0.01 and then incubated at 37°C with 5% CO2. Growth of the strains
was monitored by measuring the OD600 of the cultures every day.
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respectively, at day 70, when the experiment was stopped. With
the BCG auxotroph (MYC1552), the number of bacilli began
to decrease immediately after the infection, and no bacteria
were recovered from the lung at day 70. In the spleen and the
liver, a few colonies were recovered at day 70, when the ex-
periment was stopped.
These results established that the mutations in the purC
gene of both BCG and M. tuberculosis attenuated the virulence
of these strains in the mouse model. The experiment was
repeated with a second susceptible mouse line, C57BL/6, with
M. tuberculosis MT103 and MYC1551 but without any differ-
ences noted. MYC1551 and MYC1552 were eliminated very
efficiently, becoming almost undetectable at the end of the
experiment (day 63 for M. tuberculosis and day 70 for BCG).
However, they persisted for a while since bacteria were recov-
ered from every organ during the first 6 weeks. The main
difference in the behavior of the two purine auxotrophs thus
appears in the first week postinfection. While the M. tubercu-
losis purC mutant MYC1551 increased slightly in every organ
tested, the M. bovis BCG purC mutant MYC1552 began to
decline immediately after the infection. After this short lag
time, MYC1551 was cleared as efficiently as MYC1552.
DTH induced by the purine auxotrophs and protective effi-
cacy in the guinea pig model. To evaluate the protective effi-
cacy of the purine auxotrophs, the guinea pig was chosen
because it is much more susceptible to M. tuberculosis infection
than the mouse. Furthermore, BCG protection is easier to
demonstrate in the guinea pig. While a maximum of 1 log of
difference in the CFU number can be obtained in the lung and
spleen of unimmunized compared to BCG-vaccinated mice,
differences of 1 to 2 logs in the lung and 4 logs in the spleen are
often obtained between naive and BCG-vaccinated guinea pigs
following low-dose aerosol challenge (19).
Outbred Hartley strain guinea pigs were inoculated subcu-
taneously with 107 CFU of either BCG 1173P2, MYC1552, or
MYC1551. Three animals from each treatment group were
euthanized at 3, 6, and 9 weeks postinfection. The number of
viable mycobacteria was determined in one half of the spleen
and the right lower lobe of the lung. Three weeks postinfec-
tion, 870 6 651 CFU of BCG 1173P2 was found in the spleens
of three guinea pigs. In contrast, 90 CFU was recovered from
only one of three guinea pigs infected with MYC1551, and no
bacteria were found in any of the animals vaccinated with
MYC1552. Six and nine weeks postinfection, no bacillus was
recovered from the spleens of any animal of any of the three
treatment groups. At no time point were bacilli recovered from
the lungs of any vaccinated animal. These results show that the
purine auxotrophs are attenuated even in the highly suscepti-
ble guinea pig as well as they were in the mouse model.
The cutaneous DTH response to PPD was evaluated 9
weeks postvaccination. All of the vaccinated animals exhibited
a detectable skin test reaction against tuberculin (Table 1). The
mean induration diameters, measured 24 h following the in-
tradermal injection, were 13.9 6 0.9, 15.5 6 1.0, and 11.1 6
2.2, respectively, for the BCG-, MYC1552-, and MYC1551-
infected guinea pigs.
Nine weeks postvaccination, the remaining animals were
infected via the aerosol route with a dose empirically adjusted
to result in the inhalation of 5 to 10 viable M. tuberculosis
H37Rv bacilli per animal. Five weeks later, viable M. tubercu-
losis were recovered quantitatively from the spleen and the
lung (Fig. 6). In the lung, both MYC1551 and MYC1552 ex-
hibited a level of protection comparable with the one obtained
with BCG 1173P2, namely, 1 log of difference in the CFU
count between the vaccinated and unimmunized animals. As
expected, vaccine-induced protection was most visible in the
spleen. M. tuberculosis purC mutant MYC1551 seemed to in-
duce some level of protection, while there was no difference in
unimmunized and M. bovis BCG purC mutant-vaccinated an-
imals.
The Duncan multiple-range test indicated that there was no
significant difference in the number of tubercle bacilli recov-
ered from the lung between different groups of vaccinated
animals but that the difference between vaccinated and non-
vaccinated groups was statistically significant (P , 0.05). In the
spleen, the number of mycobacteria in BCG-vaccinated ani-
mals was significantly lower than the number in MYC1552-
vaccinated and unimmunized controls and lower (although not
FIG. 3. Persistence of MYC1551 and MYC1552 within bone marrow mac-
rophages. In this representative experiment, 5 3 104 macrophages were infected
with 5 3 104 viable bacilli and growth was measured over time. (A) M. bovis BCG
1173P2 or the BCG auxotroph (MYC1552) was used to infect the macrophages.
(B) An M. tuberculosis virulent strain (MT103), its auxotroph counterpart
(MYC1551), or MYC1551 harboring plasmid pMJ111 (carrying the purC gene)
was used to infect the macrophages. Each point represents the geometric
mean 6 SEM of six (experiment with M. bovis BCG) or four (experiment with M.
tuberculosis) independent cultures.
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significantly due to the heterogeneity of the guinea pig re-
sponses to infection in every vaccination group) than the num-
ber of mycobacteria recovered from MYC1551-vaccinated an-
imals.
DISCUSSION
With the goal of developing a novel vaccine against TB, we
constructed and evaluated the attenuation and protective effi-
cacy of purC auxotroph mutant strains of M. tuberculosis and
M. bovis BCG carrying a defect in the purine biosynthetic
pathway. This approach was justified by the fact that attenu-
ated strains are generally more potent than nonliving vaccines
in stimulating cell-mediated immune responses which are ef-
fective against intracellular pathogens (7) and because, in the-
ory, they produce most of the antigens normally expressed in
vivo by the pathogens. Thus, immune responses are stimulated
in ways which closely resemble those detected during normal
infection. Moreover, by constructing an auxotrophic strain de-
rived from M. tuberculosis, one would derive a vaccine candi-
date antigenically identical to the pathogen against which pro-
tection was desired.
As shown for other purine auxotrophs of intracellular patho-
gens which reside inside vacuoles (9, 18, 20), M. tuberculosis
(MYC1551) and M. bovis BCG (MYC1552) purine-deficient
mutants were attenuated both in an in vitro macrophage model
and in vivo in mice and guinea pigs. Since the introduction of
the purC gene on a plasmid into the M. tuberculosis auxotroph
fully restores its ability to replicate and lyse the macrophages,
one can conclude that restriction for growth inside these cells
is due to the insertional disruption of the purC gene alone and
not to polarity affecting the expression of adjacent genes.
In contrast to what was observed with their respective pa-
rental strains, the number of MYC1551 CFU in mouse bone
marrow macrophages did not increase over a 15-day period of
time but remained approximately constant, whereas the num-
ber of MYC1552 CFU steadily decreased from the first day
postinfection. In the absence of purine bases in the medium,
most likely resembling the situation within the phagosomal
compartment, both auxotrophs were unable to multiply (Fig.
FIG. 4. Persistence of M. tuberculosis MT103 and the purine auxotroph MYC1551 in mice. BALB/c mice were infected intravenously with 107 viable units of either
an M. tuberculosis virulent strain (MT103) or MYC1551, and the persistence of bacteria in three organs was measured over time. Each value represents the geometric
mean 6 SEM obtained with five different mice.
FIG. 5. Persistence of M. bovis BCG and its auxotroph counterpart, MYC1552, in mice. BALB/c mice were infected intravenously with 107 viable units of either
M. bovis BCG or MYC1552, and the persistence of bacteria in three organs was measured over time. Each value represents the geometric mean 1 SEM obtained with
five different mice.
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2). Thus, this difference in intracellular persistence between
MYC1551 and MYC1552 probably reflects the different abili-
ties of these M. tuberculosis and M. bovis BCG derivatives to
resist phagocytic cells defenses and/or to make the phagosome
in which they reside more hospitable.
The behavior of the auxotrophs in mice reflects the results
obtained in isolated macrophages: the M. tuberculosis auxo-
troph MYC1551 was progressively eliminated after a lag pe-
riod of 2 to 3 weeks during which the number of CFU in all
organs remained almost constant, whereas elimination of the
M. bovis BCG purC mutant MYC1552 began immediately after
the infection. Overall, both strains were eliminated at about
the same rate from mice. In guinea pigs, fewer MYC1551 than
BCG and no MYC1552 were found in the spleens 3 weeks
postimmunization. Finally, based on data obtained from the
macrophage and guinea pig experiments in which the same
infecting doses were used for all strains, it seems that both
MYC1551 and MYC1552 are more attenuated than BCG.
The results of the protection studies, although preliminary
because of the limited number of animals studied, indicated
that all three strains (BCG, MYC1551, and MYC1552) had
equal protective effects against an aerosol challenge with vir-
ulent M. tuberculosis H37Rv, as assessed by the reduction in
CFU in the lungs of vaccinated guinea pigs. In the spleen,
where more extensive protection is obtained, MYC1551
seemed to induce a protective effect compared to results for
unimmunized controls, although it seemed slightly less efficient
than that conferred by BCG. In the same organ, MYC1552
seemed to induce no protective response at all. The finding
that MYC1552 shows a protective effect in the lungs but not in
the spleen, unlike its M. tuberculosis counterpart and BCG,
which show protective efficacy in both organs, could reflect the
inability of the BCG auxotroph to control the dissemination of
M. tuberculosis H37Rv following the aerosol infection and,
thus, its inability to stimulate protective immunity with the
same efficiency as the two other immunizing strains.
All three strains elicited strong DTH responses 9 weeks
postinfection, suggesting that both auxotrophs are able to in-
duce cell-mediated immune responses as does the BCG vac-
cine. Therefore, the differences in the protective efficacies of
BCG, MYC1551, and MYC1552 may have resulted from dif-
ferences in the quality of the cellular immune responses that
they induce rather than in their ability to induce such re-
sponses. In fact, it is probable that an attenuated strain of
mycobacteria needs to retain a limited ability to multiply in
host cells and to disseminate and persist within the host in
order to be able to induce protective immune responses. This
idea was originally pointed out by Kanai’s work (14), in which
the protective efficacy of a streptomycin-dependent strain of
M. tuberculosis was evaluated in guinea pigs and mice. In this
system, streptomycin was used to induce the multiplication of
the immunizing strain prior to challenge with virulent H37Rv
tubercle bacilli. Experiments showed that only the M. tubercu-
losis that had multiplied during the immunization period con-
ferred protection to the animals, with nonmultiplying bacteria
displaying poor protection.
Thus, the way an attenuated strain establishes an infection in
the host, probably more than persistence in itself, seems to be
important for inducing protective immune responses. These
observations highlight the difficulty inherent in using live vac-
cines to reach the right balance between attenuation and im-
munogenicity, since overattenuated bacteria may not produce
in vivo some key antigens necessary for the induction of a
protective immunity. The physiological state of the mutant
bacilli might also influence the way their antigens are pro-
cessed inside the macrophage and, thus, presented to the T
lymphocytes.
Finally, this work provides evidence that rationally attenu-
ated strains of M. tuberculosis can protect guinea pigs against
pulmonary tuberculosis.
In further experiments with the MYC1551 and MYC1552
auxotrophs, it will be important to test whether immunizing the
guinea pigs with higher doses of bacteria (108 CFU, for exam-
ple) or with two or three doses of 107 CFU (injected 1 or 2
weeks apart) can improve the protective immune response that
FIG. 6. Protective efficacy of the different vaccine strains against low-dose
pulmonary challenge in guinea pigs. Nine weeks postvaccination, guinea pigs
were infected via the aerosol route with 5 to 10 viable M. tuberculosis organisms.
Five weeks later, these animals were euthanized and the the number of CFU of
M. tuberculosis was evaluated in the lung (A) and the spleen (B). The CFU-per-
organ values indicated are the geometric means 1 SEM; n is the number of
animals used.
TABLE 1. Tuberculin skin test on guinea pigs injected via the
intradermal route with 100 tuberculin units 9 weeks postinfectiona
Vaccination
group
Induration diam (mm)
Individual determinations Mean 6 SEM
BCG 13.0, 12.5, 17.5, 13.5, 13.0 13.9 6 0.9
MYC1552 16.0, 17.0, 13.5 15.5 6 1.0
MYC1551 5.0, 12.0, 18.5, 11.0, 9.0 11.1 6 2.2
a In all cases, the control group exhibited no reaction.
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they induce. It will also be important to test whether MYC1551
and MYC1552 induce long-term protection by performing the
aerosol challenge with virulent M. tuberculosis 4 or 6 months
postimmunization. Also of great interest would be to evaluate
the protective efficacy of the M. tuberculosis attenuated strains
not only in the guinea pig model of tuberculosis but also in
other models in which the BCG appears to be less potent and
where improvements are thus required, such as models reflect-
ing the case of individuals frequently exposed to environmental
mycobacteria or developing TB from the reactivation of dor-
mant bacilli.
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